Novo Nordisk A/S – Consensus Indicates Potential 18.6% Upside

Broker Ratings

Novo Nordisk A/S found using ticker (NVO) have now 2 analysts covering the stock. The analyst consensus points to a rating of ‘Hold’. The range between the high target price and low target price is between 80.17 and 78.88 calculating the mean target price we have 79.52. With the stocks previous close at 67.06 this now indicates there is a potential upside of 18.6%. The day 50 moving average is 71.76 and the 200 moving average now moves to 69.99. The market capitalisation for the company is $155,946m. Find out more information at:

Novo Nordisk A/S, a healthcare company, engages in the research, development, manufacture, and marketing of pharmaceutical products worldwide. It operates in two segments, Diabetes and Obesity care, and Biopharm. The Diabetes and Obesity care segment provides products in the areas of insulins, GLP-1 and related delivery systems, oral antidiabetic products, obesity, and other chronic diseases. The Biopharmaceuticals segment offers products in the areas of haemophilia, growth disorders, and hormone replacement therapy. The company collaboration agreements with Lund University to develop treatment for Parkinson’s diseases; and bluebird bio to develop genome editing treatments for children and adult patients. The company was founded in 1923 and is headquartered in Bagsvaerd, Denmark.

You can now share this on Stocktwits, just click the logo below and add the ticker in the text to be seen.

Share on Stocktwits

Good news travels fast (but only if you make that happen):

Share on twitter
Share on linkedin
Share on facebook
Share on email
Share on whatsapp